NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

Hoffy, with the absolutely startling enhancement of DCVax-L's efficacy that has been shown when pembrolizumb and poly-ICLC are added to the regimen, I can see that a trial of the combo should be mounted if only to set a benchmark for the efficacy of the combination against which all future trials of different drugs or combinations can be adjudged.
However, such a further study should not delay DCVax-L's contribution both to saving lives and to replensihing NWBO's coffers because once it is licenced every neuro-oncologist who has kept up to date with what is going on in the DCVax-L firmament is going to routinely prescribe the triple combination unless such a "benchmark" study were to show (unbelievably on current findings) that the addition of one or both extra components added nothing to DCVax-L's efficacy.